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The FFAT motif is a targeting signal responsible for
localizing a number of proteins to the cytosolic sur-
face of the endoplasmic reticulum (ER) and to the nu-
clear membrane. FFAT motifs bind to members of the
highly conserved VAP protein family, which are teth-
ered to the cytoplasmic face of the ER by a C-terminal
transmembrane domain. We have solved crystal struc-
tures of the rat VAP-A MSP homology domain alone
and in complex with an FFAT motif. The co-crystal
structure was used to design a VAP mutant that dis-
rupts rat and yeast VAP-FFAT interactions in vitro.
The FFAT binding-defective mutant also blocked func-
tion of the VAP homolog Scs2p in yeast. Finally, over-
expression of the FFAT binding-defective VAP in COS7
cells dramatically altered ER morphology. Our data
establish the structural basis of FFAT-mediated ER
targeting and suggest that FFAT-targeted proteins
play an important role in determining ER morphology.
Introduction
The endoplasmic reticulum (ER) is a multifunctional or-
ganelle. After translocation across the ER membrane,
secreted proteins fold, undergo posttranslational modi-
fication, and assemble into multiprotein complexes in
the ER lumen (Baumann and Walz, 2001). Additionally,
the cytosolic surface of the ER membrane is a major
site for lipid biosynthesis, and many peripheral mem-
brane proteins are localized to the cytosolic surface of
the ER membrane (Baumann and Walz, 2001). While the
mechanism by which proteins are targeted for translo-
cation into the ER lumen is well characterized, it is not
well understood how proteins are targeted to the cyto-
solic surface of the ER. Recent work has identified a
targeting signal (the FFAT motif) responsible for tar-*Correspondence: brunger@stanford.edugeting cytosolic proteins to the surface of the ER
(Loewen et al., 2003) and to the nuclear membrane
(Brickner and Walter, 2004). The FFAT motif (FFAT
stands for diphenylalanine [FF] in an acidic tract) has
the consensus amino acid sequence EFFDAxE (Loewen
et al., 2003). This motif was identified because it is con-
served in a large family of oxysterol binding protein-
related proteins (ORPs) (Figure 1A and Figure S1A; see
the Supplemental Data available with this article online
[Loewen et al., 2003]). ORPs are regulators of lipid me-
tabolism that are targeted by their FFAT motifs to the
cytosolic surface of the ER (Loewen et al., 2003). In
both yeast and mammals, proteins containing exposed
FFAT motifs are targeted to ER membranes by interac-
tions with VAP proteins (VAP stands for VAMP-associ-
ated protein; VAMP stands for vesicle-associated
membrane protein) (Loewen et al., 2003; Wyles et al.,
2002).
VAP proteins are composed of three conserved do-
mains. These include an N-terminal immunoglobulin-like
β sheet, a central coiled-coil domain, and a C-terminal
transmembrane domain (Figure 1A). The N-terminal do-
main shares 22% sequence identity with the well-char-
acterized major sperm protein (MSP) (Figure 1A and
Figure S1B) (Roberts and Stewart, 2000). However, it is
unclear whether VAP proteins share a common func-
tion. In metazoans, in addition to its role in recruiting
FFAT motif-targeted proteins to ER membranes (Amari-
lio et al., 2005; Brickner and Walter, 2004; Kagiwada et
al., 1998; Loewen and Levine, 2005; Loewen et al.,
2003; Skehel et al., 2000; Soussan et al., 1999; Wyles
et al., 2002; Wyles and Ridgway, 2004), VAP has been
proposed to function in vesicle trafficking (Foster et al.,
2000; Skehel et al., 1995), and in the organization of
microtubule networks (Amarilio et al., 2005; Pennetta et
al., 2002). Scs2p, the yeast homolog of VAP, binds FFAT
motifs, and yeast lacking Scs2p mislocalize FFAT-tar-
geted proteins to the cytoplasm (Loewen et al., 2003).
In addition to its role in recruiting ORPs to the ER,
Scs2p has also been implicated in transcriptional regu-
lation of the INO1 gene that encodes an important
phospholipid biosynthetic protein (Brickner and Walter,
2004; Kagiwada et al., 1998). Strains lacking SCS2 are
unable to activate the INO1 gene and cannot grow in
the absence of inositol. Opi1p, a transcriptional repres-
sor of INO1 that possesses an FFAT motif (Figure 1A),
is regulated by Scs2p on the nuclear membrane (Brick-
ner and Walter, 2004; Loewen et al., 2003).
Here, we present the crystal structure for a VAP-FFAT
motif interaction. We find that the specific molecular
interactions between FFAT and VAP are highly con-
served from yeast to mammals. Based on our structure
of the VAP-FFAT complex, we designed mutants of the
yeast VAP homolog Scs2p that are defective for FFAT
motif binding. These mutants were defective for activa-
tion of INO1, indicating that FFAT-mediated binding of
Scs2p to Opi1p is essential for this activation event.




























rFigure 1. Domain Diagrams and Gel Shift Assays
l(A) Domain organization diagrams of VAP, ORP1, and Opi1p. Do-
main abbreviations are: major sperm protein homology domain,
MSP; coiled-coil domain, CC; transmembrane domain, T; ankyrin t
repeats, ANK; plekstrin homology domain, PH; FFAT motif with se- l
quence related to EFFDAxE (Loewen et al., 2003), F; OSBP-related a
protein lipid binding domain, ORP; Sin3p binding domain, S; basic
dleucine zipper, Z.
t(B) Native gel shift assay. VAP-A (1–125) alone (lane 1) migrates at
Ba different rate than VAP-A (1–125) plus equimolar amounts of the
ORP1 FFAT peptide SEDEFYDALS (lane 2), demonstrating that w
VAP-A (1–125) binds FFAT motifs directly. VAP-A (1–125) K87D/ a
M89D migrates faster than VAP-A (1–125) (lanes 1 and 3). The mo- e
bility of VAP-A (1–125) K87D/M89D is not affected by added FFAT
2motif (lanes 3 and 4), suggesting that VAP K87D/M89D does not
dbind FFAT motifs. Yeast Scs2p binds to the FFAT motif peptide from
byeast Opi1p (lanes 5 and 6). The yeast Opi1p peptide DDEEFF-
DASE caused a mobility shift of Scs2p (1–224) (lanes 5 and 6). The m
mobility of Scs2p (1–224) K84D/L86D is not affected by added pep- 5
tide (lanes 7 and 8). FFAT peptides alone were not visible on the i
native gels used in these experiments.
V
a
afective for FFAT binding alters ER morphology in dis-
stinct patterns, suggesting that VAP and FFAT proteins





(VAP Interacts with Proteins Containing FFAT Motifs
To investigate VAP function, we analyzed the ability of p
oVAP proteins to interact with putative binding partners
that were suggested in previous reports (Pennetta et i
tal., 2002; Skehel et al., 2000; Weir et al., 2001; Wyles
et al., 2002). We were able to reproduce the reported s
dinteraction between VAP homologs and proteins con-
taining FFAT motifs (Loewen and Levine, 2005; Loewen L
det al., 2003) with purified proteins in vitro. However, weound no evidence for direct interactions of cytosolic
ortions of VAP with cytosolic portions of SNARE pro-
eins or with tubulin or microtubules (data not shown).
he stoichiometry of the VAP-FFAT interaction was de-
ermined by size exclusion chromatography coupled to
n-line multiangle laser light scattering (SEC-MALLS);
ecombinant rat ORP1 (454–546) (which contains the
RP1 FFAT motif) interacts with rat VAP-A (1–125) in a
:1 complex (Figure S2). The interaction between VAP
roteins and FFAT motifs was also confirmed by a na-
ive gel shift assay (Figure 1B). VAP-A (1–125) alone
lane 1) migrates at a different rate than VAP-A (1–125)
lus equimolar amounts of the ORP1 FFAT peptide
EDEFYDALS (lane 2). We obtained similar results for
he yeast Scs2p-Opi1p interaction (Figure 1B, lanes 5
nd 6).
rystal Structure of the Rat VAP-A
SP Homology Domain
n order to obtain a stable fragment of VAP-A that is
uitable for crystallization, we performed limited trypsin
igestion of the cytosolic portion of rat VAP-A (residues
–219). We obtained a stable fragment consisting of
AP-A residues 1–123, as measured by MALDI mass
pectrometry (data not shown). Secondary structure
rediction (Rost and Liu, 2003) suggested that VAP-A
esidue 125 is the end of the β strand that contains
esidue 123. We thus expressed, purified, and crystal-
ized VAP-A (1–125).
The crystal structure of selenomethionine-substi-
uted rat VAP-A (1–125) was solved to dmin = 1.7 Å reso-
ution using diffraction data from a multiwavelength
nomalous dispersion (MAD) experiment (Table 1) (Hen-
rickson, 1991). As expected from sequence homology,
he fold of VAP-A (1–125) is the same as that of MSP.
oth are seven-stranded immunoglobulin-like β sand-
iches with s-type topology, and their Cα backbones
lign with an rmsd of 2.0 Å over 109 residues (Bullock
t al., 1996). Although they share the same fold and
2% sequence identity, VAP-A (1–125) and MSP have
istinct surface electrostatic properties (Figure 2) and
ehave differently in solution. While MSP forms a sym-
etric dimer (Figures 2C and 2D) with a Kd of less than
0 nM (Haaf et al., 1996), VAP-A (1–125) is monomeric
n solution, as measured by SEC-MALLS (Figure S2).
AP-A (1–125) crystallizes with one molecule in the
symmetric unit, but forms a symmetric crystal contact
cross a crystallographic 2-fold interface with a buried
urface area of 440 Å2. This interface is centered on a
ighly conserved sequence that contains Cys53. Cys53
esidue pairs show a mixture of reduced and disulfide
onded conformations across this crystallographic
nterface. This disulfide bond may represent an artifact
f crystallization. It is therefore noteworthy that VAP-A
1–125) is monomeric in solution and that, at the high
rotein concentration required for crystallization, none
f the crystal contacts correspond to the MSP dimer
nterface. Indeed, critical residues in the MSP dimeriza-
ion interface, such as Val18 and Tyr29, are not con-
erved in VAP proteins (Bullock et al., 1996). These resi-
ues are instead replaced in VAP-A by polar residues
ys17 and Thr28. We conclude that VAP MSP homology
omains do not dimerize in the same way as MSP.
VAP-FFAT Complex Structure
1037Table 1. VAP-A (1–125) Se-MAD Crystallographic Data Collection, Phasing, and Refinement Statistics
Crystallographic Data Statistics
Space group P42212
Cell dimensions a = 48.2 Å, b = 48.2 Å, c = 112.4 Å
Number of
dmin (Å) Reflections Completeness <I>/<σ> Rsyma Multiplicity
λ1 inflection (0.9795 Å) 1.7 27,548 98.0 (99.8)b 16.5 (8.3) 10.1 (42.0) 12.9 (11.9)
λ2 peak (0.9793 Å) 1.7 27,537 98.1 (99.8)b 15.5 (7.8) 10.2 (41.0) 12.9 (12.1)
λ3 remote (0.9649 Å) 1.7 27,524 98.0 (99.8)b 17.2 (8.1) 9.8 (40.0) 12.9 (11.8)
MAD Phasing Statistics
Observed Dispersive and Bijvoet Ratiosc
λ1 λ2 λ3
λ1 0.0585 0.0537 0.0749
λ2 0.1146 0.0637
λ3 0.0724
Se-MAD Figure of Merit 0.79 (0.70)
Refinement Statistics
Resolution range 55–1.7 Å
Number of reflections 27,484
Rd 22.1% (27.6%)
Rfreee 25.4% (30.0%)
Luzatti coordinate error 0.22 Å
Crossvalidated Luzatti coordinate error 0.26 Å
Bond length deviation 0.005 Å
Bond angle deviation 1.36°
Average B factor 20.5 Å2
Bonded main chain atom B factor rmsd 1.45 Å2
Bonded side chain atom B factor rmsd 2.53 Å2
Residues in the most favored f-ψ region 94.5%
Residues in generously allowed region 5.5%
Residues in disallowed region 0.0%
a Rsym = ShSi|Ii(h) − <I(h)>|/ShSi|Ii(h)|.
b Values in parentheses are for the highest resolution bin.
c Values are <(|F|)2>1/2/<|F|2>1/2, where |F| is the dispersive (off-diagonal element), or Bijvoet difference (diagonal elements), computed
between 500 and 1.7 Å resolution.
d R = Σ(|Fobs| − k|Fcalc|)/Σ|Fobs|.
e Rfree is the R value obtained for a test set of reflections, consisting of a randomly selected 10% subset of the diffraction data, not used
during refinement.Crystal Structure of a VAP-FFAT Complex
We next sought to determine the structural basis for
the interaction between VAP proteins and FFAT motifs.
We solved the structure of rat VAP-A (1–125) in complex
with the rat ORP1 FFAT motif (residues 472-SEDEFY-
DALS-481) using diffraction data from a single wave-
length anomalous dispersion (SAD) experiment and a
native diffraction data set to dmin = 1.9 Å resolution (Ta-
ble 2) (Hendrickson, 1991). The structure of VAP-A
(1–125) is subtly changed by FFAT binding. VAP Cα
backbones from our structures align with an rmsd of
1.3 Å over 113 residues. The FFAT motif binds across
VAP β strands F, E, C, and D1 (Figure 3A). FFAT binding
causes small (0.1–0.5 Å) changes in the position of
backbone atoms within these β strands and substantial
changes (2–4 Å) in the position of several side chain
atoms that accommodate FFAT binding. We observed
clear electron density for main and side chain atoms of
ORP1 FFAT residues 476–481 and main chain atoms of
residues 473–475 (Figure 3B). The FFAT residue Phe476
binds VAP in a hydrophobic pocket created by the ali-
phatic amino acid side chains of several residues (Fig-
ure 3B). It has extensive hydrophobic van der Waalscontacts with VAP-A residue Met89 and with aliphatic
portions of side chains from VAP-A residues Lys45,
Thr47, Lys87, and Lys118 (Figure 3B).
The FFAT motif binds VAP on a positive patch that is
in a highly conserved region on the VAP protein surface
(Figures 3C and 3D). Part of the FFAT binding site on
the yeast VAP homolog Scs2p was recently identified
by a mutagenic screen (Loewen and Levine, 2005). This
screen identified residues equivalent to VAP-A Lys45,
Thr47, Lys87, and Lys118 as essential for VAP-FFAT in-
teractions. Our structure reveals that, rather than in-
teracting with negative side chains in FFAT motifs, ali-
phatic portions of these side chains form part of the
hydrophobic pocket in which FFAT residue Phe476
binds. Additionally, our structure shows the full comple-
ment of VAP-FFAT interactions. FFAT residues 477 and
479–481 are bound to VAP by a network of backbone-
backbone hydrogen bonds. Although the FFAT consen-
sus sequence is EFFDAxE, the rat ORP1 FFAT se-
quence has the sequence 472-SEDEFYDALS-481. In
our structure, FFAT residue Tyr479 is ordered but lacks
substantial interactions with VAP. It is restrained by
weak van der Waals interactions with several residues,
Structure
1038Figure 2. Comparison of Surface Electro-
static Characteristics of VAP-A (1–125) and
MSP-1
(A and B) Two orientations of the VAP-A
(1–125) monomer in surface representation
colored to show the electrostatic potential cal-
culated APBS, as implemented in Pymol by
using the CHARMM force field. The electro-
static surface was contoured from −10 kT/e
(red) to +10 kT/e (blue).
(C and D) Two orientations of the MSP-1
dimer equivalent to the VAP-A (1–125) orien-
tations in (A) and (B) with one monomer in
surface representation and the partner
monomer in ribbon representation (orange).
The MSP-1 surface is colored to show the
electrostatic potential calculated by APBS, as
implemented in Pymol using the CHARMM
force field. The electrostatic surface was
contoured from −10 kT/e (red) to +10 kT/e
(blue).and its γ hydroxyl group lacks a hydrogen bonding part- s
sner. This lack of strong interactions explains the ob-
served variation between Phe or Tyr in the FFAT proteins s
oidentified to date and suggests that FFAT sequences with
other residues at this position may be able to bind VAP. i
aThe side chain of Ala479 binds VAP in a small hy-
drophobic pocket created by aliphatic portions of side p
mchains from residues Val44, Thr46, and Val54.
Although VAP-A (1–125) interacts with an FFAT motif r
cas a 1:1 complex, as determined by SEC-MALLS (Fig-
ure S2), VAP-FFAT crystals are composed of two VAP t
tMSP domains with two FFAT motifs bound between
them (Figures 4A and 4B). As measured by SEC- t
wMALLS, the VAP coiled-coil domain causes dimeriza-
tion of VAP-A (1–219) (data not shown). The transmem- a
abrane domain, which contains the dimerization motif
GxxxG (Russ and Engelman, 2000), is also likely to f
cdrive VAP dimerization. Thus, the observed crystal
packing may mimic the high local VAP MSP homology e
mdomain concentration that would result from coiled-coil
and transmembrane domain-induced VAP dimerization.
Several additional observations corroborate this hy- F
Tpothesis. The VAP-VAP, VAP-FFAT, and FFAT-FFAT in-
teractions within the 2:2 complex bury 1700 Å2 of sur- V
sface area and may explain the conservation of residues
in FFAT motifs that are not explained by the 1:1 VAP- p
SFFAT complex alone (Figure 4). In particular, of the resi-
dues in the EFFDAxE FFAT consensus sequence, the l
tAsp following the single ring aromatic residues in FFAT
motifs (Asp478 in ORP1) is strictly conserved among f
pFFAT proteins identified to date (Figure S1A). Asp478
forms symmetric hydrogen bonds between the two V
FFFAT motifs within a 2:2 complex (Figure 4C). Theseymmetric hydrogen bonds may explain the high con-
ervation of Asp478 in FFAT motifs (Figure S1A). As de-
cribed above, the side chain of FFAT residue Tyr477 is
nly weakly restrained by the VAP surface to which it
s primarily bound. This residue is further restrained by
hydrophobic van der Waals contact with an aliphatic
ortion of the Asp478 side chain from the second FFAT
otif within the 2:2 complex. Another argument for the
elevance of the 2:2 complex is that it could form in the
ontext of full-length VAP and full-length ORP1: the C
ermini of the two VAP-A (1–125) domains project from
he same face of a 2:2 complex (Figure 4A), and the
ermini of the bound ORP1 peptide are oriented in a
ay that is consistent with VAP on membranes binding
n FFAT motif of a large cytosolic protein (Figures 4A
nd 4B). Thus, the 2:2 complex could form between
ull-length VAP and FFAT proteins with both VAP coiled-
oil domains dimerized and both VAP molecules teth-
red to the same membrane by their C-terminal trans-
embrane domains (Figure 4A).
FAT Binding Is a Conserved VAP Function
he FFAT motif binding site is highly conserved among
AP protein family members but is not conserved in the
tructurally similar MSP-1 (Figure 3D). This observation
rompted us to assess whether the yeast VAP homolog
cs2p interacts with FFAT motifs using the same mo-
ecular mechanism as that of rat VAP-A and to assess
he functional significance of FFAT interactions for Scs2p
unction. We used the structure of the VAP-FFAT com-
lex to construct point mutations on the surface of rat
AP-A that we predicted would specifically prevent
FAT binding. We chose to mutate two residues on the
VAP-FFAT Complex Structure
1039Table 2. VAP-FFAT Complex: Crystallographic Data Collection, Phasing, and Refinement Statistics
Crystallographic Data Statistics
Space group P1
Cell dimensions a = 50.1 Å, b = 50.0 Å, c = 90.3 Å, α = 90°, β = 90°, γ = 60°
Number of
dmin (Å) Reflections Completeness <I>/<σ> Rsyma Multiplicity
Se-SAD (0.9794 Å) 2.8 37,329 99.0 (99.9)b 14.1 (9.4) 9.3 (21.0) 7.9 (7.8)
Native (1.0331 Å) 1.9 59,506 99.4 (100.0)b 10.2 (3.8) 6.0 (34.0) 4.0 (4.0)
SAD Phasing Statistics
Se-SAD FOM 0.38 (0.34)
Se-SAD FOMDM 0.84 (0.79)
Refinement Statistics
Resolution range 14.65–1.9 Å
Number of reflections 53,477
Rc 21.5% (26.6%)
Rfreed 26.1% (32.3%)
Luzatti coordinate error 0.20 Å
Crossvalidated Luzatti coordinate error 0.18 Å
Bond length deviation 0.031 Å
Bond angle deviation 2.49°
Average B factor 26.3 Å2
Bonded main chain atom B factor rmsd 1.79 Å2
Bonded side chain atom B factor rmsd 3.47 Å2
Average NCS rmsd (all atoms) 0.03 Å
Residues in the most favored f-ψ region 94.9%
Residues in generously allowed region 5.1%
Residues in disallowed region 0.0%
a Rsym = ShSi|Ii(h) − <I(h)>|/ShSi|Ii(h)|.
b Values in parentheses are for the highest resolution bin.
c R = Σ(|Fobs| − k|Fcalc|)/Σ|Fobs|.
d Rfree is the R value obtained for a test set of reflections, consisting of a randomly selected 10% subset of the diffraction data, not used
during refinement.VAP surface that interact with FFAT residue Phe476
(Figure 3B) to acidic residues by making the double
point mutation K87D/M89D. As expected, in a native
gel, the band corresponding to the VAP-A (1–125)
K87D/M89D double mutant does not shift upon addi-
tion of the FFAT peptide (compare lanes 3 and 4 of Fig-
ure 1B). Wild-type and mutant VAP-A (1–125) are both
folded, as measured by circular dichroism, and are both
monodisperse and monomeric in solution, as measured
by SEC-MALLS (data not shown).
Mutating the homologous residues (K84D/L86D) in
the yeast VAP homolog Scs2p disrupted Scs2p interac-
tions with the FFAT motif of the yeast protein Opi1p
in vitro (Figure 1B, lanes 7 and 8). The gel shift experi-
ments thus confirm that Scs2p residues K84 and L86
are equivalent to rat VAP-A residues K87 and M89 and
that both proteins probably bind to FFAT motifs by the
same mechanism. We next tested if the K84D/L86D
mutant of Scs2p was functional in yeast. Strains lack-
ing SCS2 are unable to activate INO1 and cannot grow
in the absence of inositol. Expression of wild-type
Scs2p in an scs2D mutant strain allowed activation of
INO1 and growth on medium lacking inositol. In con-
trast, Scs2p K84D/L86D failed to complement this
growth phenotype (Figure 5A). Western blot analysis of
total protein from yeast strains expressing wild-type or
mutant Scs2p confirmed that the K84D/L86D mutant
was expressed and stable in yeast (Figure 5B). Thus,
the essential function of Scs2p in activating INO1 re-quires its evolutionarily conserved FFAT binding ac-
tivity.
Overexpression of VAP or an FFAT Binding Mutant
Causes Altered ER Morphology
Several recent reports suggest that VAP-FFAT interac-
tions may regulate ER morphology (Amarilio et al.,
2005; Wyles et al., 2002; Wyles and Ridgway, 2004).
VAP-A (1–242) overexpressed in COS7 cells as a C-ter-
minal GFP fusion protein is localized to perinuclear and
ER membranes and overlays with staining of the ER
marker calreticulin (Figure 6A), but not with microtu-
bules (Figure 6B). VAP-GFP overexpression resulted in
the range of ER phenotypes illustrated in Figures 6A–
6E. Overexpression of the VAP-A (1–242) K87D/M89D
mutant, which disrupts FFAT binding, resulted in ER
phenotypes ranging from those seen with overexpres-
sion of wild-type VAP to, in approximately 1%–10% of
transfected cells, a pattern of regularly spaced patches
of increased fluorescence as shown in Figures 6G and
6H. These patches are continuous with normal-appear-
ing reticulated ER and colocalize with ER markers. This
regular pattern of dense patches was never observed
with overexpression of wild-type VAP. Since the K87D/
M89D double point mutation does not affect VAP fold-
ing and structure or cause aggregation, it is likely that
the observed pattern of dense patches results from the
disruption of VAP-FFAT interactions.
Structure
1040Figure 3. ORP1 FFAT Motif Interaction with the VAP-A (1–125) FFAT Binding Site
(A) The FFAT motif of ORP1 (shown in stick representation) binds across VAP-A (1–125) (shown in ribbon representation) β strands F, E, C,
and D1.
(B) A zoomed view of VAP-A (1–125) (white carbon atoms) with bound FFAT motif (yellow carbon atoms) is shown in an orientation similar to
that in (A). Electron density for the FFAT motif from a phase-combined, σA-weighted simulated annealing omit map that omitted FFAT peptide
residues from map calculations is shown as blue mesh. ORP1 FFAT residue F476 binds in a cavity bordered by aliphatic side chains that
include VAP Lys87 and Met89.
(C) The ORP1 FFAT motif binds VAP on a positive surface. The ORP1 FFAT peptide is shown in stick representation. VAP is oriented as in (A),
and the surface is colored according to electrostatic potential as in Figure 2.
(D) The ORP1 FFAT motif binds in a region that is highly conserved among VAP homologs but not in the related protein MSP-1. Residues
shown in red are identical among VAP homologs but are not conserved in MSP-1 and correspond to those marked with a red star in the
alignment in Figure S1B. Residues shown in pink are similar among VAP homologs but are not conserved in MSP-1 and correspond to those
marked with a pink triangle in the alignment in Figure S1B. Residues shown in white are conserved in VAP homologs and in MSP-1. Residues
shown in gray are not conserved among VAP homologs.Implications of the VAP-FFAT Interaction m
tThe VAP-FFAT co-crystal structure reveals the structural
basis for VAP binding of FFAT motif-containing pro- F
Lteins. We used the VAP-FFAT structure to design a sta-
ble VAP double point mutant that, although properly s
Mfolded, is unable to bind FFAT motifs. We used this mu-
tant to functionally characterize VAP-FFAT interactions
iand their conservation. We also characterized the ef-
fects of VAP protein overexpression on ER morphology t
tin COS7 cells.
The VAP-FFAT structure should facilitate analysis of F
mfuture questions concerning VAP interactions with FFATotifs or with other proteins. For instance, we predict
hat a human isoform of VAP, VAP-C, is unable to bind
FAT motifs. Among other changes, VAP-C replaces
ys87 with His and Met89 with Ser. These changes are
trikingly similar to those that we created in the K87D/
89D mutant that lacks FFAT binding.
It is conceivable that FFAT proteins compete for VAP
nteractions. Thus, the primary sequence variability and
he relative affinities of various FFAT motifs (Figure S1A)
hat bind VAP proteins need to be analyzed. Our VAP-
FAT structure explains much, but not all, of the pri-
ary sequence conservation observed in FFAT motifs.
VAP-FFAT Complex Structure
1041Figure 4. The VAP-FFAT 2:2 Complex
(A and B) The VAP-FFAT complex observed in the crystal structure buries two FFAT motifs (shown in stick representation) between two
VAP-A (1–125) domains (shown in ribbon representation). (A) and (B) show the VAP-FFAT complex from two views related by the indicated
90° rotation. VAP residue Cys53 is colored red to orient the viewer. (A) illustrates a plausible orientation for the VAP-FFAT complex on
membranes. VAP coiled-coil domains (residues 164–192) are shown in dark blue, and VAP transmembrane domains (residues 223–241) are
shown in light blue.
(C) Schematic drawing of interactions between the two FFAT motifs and between VAP and FFAT motifs. This panel shows the same orientation
as that in (B). The background behind VAP molecules is colored to match the VAP chains in (B). Hydrophobic van der Waals contacts are
indicated by colored bars.The primary VAP-FFAT interaction includes the first sin-
gle ring aromatic residue in the EFFDAxE FFAT consen-
sus sequence that binds in a hydrophobic cavity on
VAP. The orientation of Phe476 in our structure sug-
gests the possibility that FFAT motifs with Tyr at this
position may still bind in a similar fashion. The second-
ary interactions in the 2:2 complex observed in VAP-
FFAT crystals explain the high conservation of the Asp
residue in the EFFDAxE FFAT consensus sequence. It
is also noteworthy that the side chain for the first Glu
in the EFFDAxE FFAT consensus sequence is not or-
dered in our structure. This may suggest that this resi-
due is not absolutely conserved in FFAT motifs. Simi-
larly, there are a variety of potential hydrogen bonding
partners for the final Glu in the EFFDAxE FFAT consen-
sus sequence. This coincides with the observed se-
quence heterogeneity within previously identified FFAT
motifs. We propose that a less stringent definition ofthis motif sequence is required and that a wider variety
of cytosolic proteins may be targeted to VAP on ER
membranes than has been anticipated.
Experimental Procedures
Expression and Purification
DNAs encoding Rattus norvegicus VAP-A and ORP1 41–130 were
cloned using standard methodology from a brain cDNA library
(Clontech) and were inserted into the pCR-Blunt II-TOPO vector
(Invitrogen). Fragments corresponding to VAP amino acid residues
1–125 and 1–219 and ORP1 residues 454–546 were subcloned into
the pGEX-4T expression vector (Pharmacia) and sequenced. Resi-
dues 1–125 or 1–219 of rat VAP or residues 454–546 of ORP1 were
expressed as N-terminal glutathione-S-transferase (GST) fusion
proteins in E. coli. BL21 (Novagen) cells were transformed with ex-
pression vector and were grown in a BIOFLO3000 fermenter (New
Brunswick) to an OD600 of 30 in ECPYM1 media (Bernard and Pay-
ton, 1995) with 0.1 mg/ml ampicillin at 37°C. The temperature was



























Expression of a mutant of the yeast VAP homolog Scs2p that can- (
not bind the FFAT motif fails to complement the inositol auxotrophy b
of an scs2 yeast strain. F
(A) Mutant scs2 strain was transformed with CEN/ARS plasmids t
expressing SCS2 or scs2-K84D/L86D. The scs2 strain trans- t
formed with the empty vector failed to grow on media lacking inosi- H
tol. Expression of wild-type Scs2p from the plasmid pSCS2 res- i
cued this growth defect. Expression of the mutant Scs2p K84D/ a
L86D failed to complement the growth phenotype, indicating that e
this mutant is unable to activate transcription of the INO1 gene. (
(B) Immunoblot analysis of Scs2p steady-state protein levels. Equal o
amounts of whole-cell yeast protein extract were separated by l
SDS-PAGE and transferred to nitrocellulose. Blots were probed p
with rabbit anti-Scs2p serum. Pated with 1 mM IPTG for 4 hr. Cells were harvested, flash frozen in
Sliquid nitrogen, and stored at −80°C for later use. Selenomethio-
cnine-substituted protein was prepared by growing BL21 cells in M9
bminimal media and inhibiting methionine biosynthesis in the pres-
bence of selenomethionine as described (Van Duyne et al., 1993).
(Expression was induced from the pGEX-4T vector by addition of 1
CmM IPTG after the temperature was shifted from 37°C to 30°C at
wan OD600 of 1.5. After 4 hr of induction, cells were harvested, flash
ofrozen, and stored for later use. For protein purification, 30 g frozen
zbacterial cells were resuspended in 200 ml lysis buffer consisting
Vof 50 mM Tris (pH 8.0), 250 mM NaCl, 5 mM EDTA, and 10 mM
mDTT and were lysed using a pneumatic cell cracker at 16,000 PSI
A(Microfluidics). The lysate was then centrifuged in a JA-14 rotor
c(Beckman) at RCF (avg) 18,879 for 60 min, and the supernatant was
sincubated in batch with glutathione-sepharose resin (Pharmacia) at
u4°C for 1 hr with gentle stirring. Fusion proteins were retained on
othe beads and were washed three times with four bed volumes of
2lysis buffer, then for three times with four bed volumes of thrombin
Cbuffer (50 mM Tris [pH 8.0], 250 mM NaCl, 13 mM 2-mercapto-
methanol, 5 mM CaCl2). The beads were then resuspended with
athrombin buffer and incubated with w50 g bovine α-thrombin
(Haematologic Technologies) at 4°C for 6 hr with slow mixing by
rotation. After thrombin cleavage, the VAP or ORP1 protein-contain- C
Cing supernatants were dialyzed into mono-S buffer [50 mM MES
buffer (pH 6), 50 mM NaCl, 10 mM DTT], respectively. VAP proteins w
bwere loaded onto a 10/10 mono-S column (Pharmacia) and eluted
with a linear gradient of sodium chloride from 50 mM to 500 mM. w
tORP1 proteins were loaded onto a 10/10 mono-Q column (Phar-
macia) and eluted with linear gradient of sodium chloride from 100 S
(mM to 500 mM. VAP proteins were further purified by gel filtration
chromatography on a Superdex 75 16/60 column (Pharmacia), then t
wdialyzed into milli-Q water with 10 mM DTT and concentrated to 25
mg/mL before flash freezing small aliquots in liquid nitrogen for (torage at −80°C. ORP1 proteins were dialyzed into 20 mM HEPES
pH 7.4), 100 mM NaCl, 10 mM DTT and concentrated to 25 mg/mL
efore flash freezing small aliquots in liquid nitrogen for storage
t −80°C. Protein concentrations were calculated from absorbance
easurements under denaturing conditions by using theoretical
olar extinction coefficients.
Peptides corresponding to rat ORP1 residues 472–481 (SEDEFY
ALS) and yeast Opi1p residues 197–206 (DDEEFFDASE) were
ynthesized by Biopeptide LLC. Peptides were resuspended in
ater before flash freezing small aliquots for later use.
Yeast Scs2p genomic DNA was amplified from genomic DNA and
as inserted into the pCR-Blunt II-TOPO vector (Invitrogen). A frag-
ent corresponding to Scs2p amino acid residues 1–224 was sub-
loned into the pet28c expression vector (Pharmacia) and se-
uenced. Scs2p (1–224) was expressed as an N-terminal 6xHis
usion protein in E. coli. BL21 (DE3) cells were transformed with
xpression vector and grown to an OD600 of 1.5 in LB medium with
.1 mg/ml kanamycin at 37°C. The temperature was shifted to
0°C, and heterologous protein expression was then initiated with
mM IPTG for 5 hr. Cells were harvested, flash frozen in liquid
itrogen, and stored at −80°C for later use. For protein purification,
ells were resuspended in lysis buffer consisting of 50 mM HEPES
pH 7.5), 150 mM NaCl, and 10 mM 2-mercaptoethanol and were
ysed using a pneumatic cell cracker at 16,000 PSI (Microfluidics).
he lysate was then centrifuged in a JA-14 rotor (Beckman) at RCF
avg) 18,879 for 60 min, and the supernatant was incubated in
atch with Ni-NTA resin (Qiagen) at 4°C for 2 hr with gentle mixing.
usion proteins were retained on the beads and were washed three
imes with four bed volumes of lysis buffer plus 20 mM imidazole,
hen for three times with four bed volumes of elution buffer (50 mM
EPES [pH 7.5], 150 mM NaCl, 10 mM 2-mercaptoethanol, 200 mM
midazole). Fractions containing fusion protein were then pooled
nd dialyzed into 50 mM HEPES (pH 7.5), 10 mM 2-mercapto-
thanol overnight in the presence of w50 g bovine α-thrombin
Amersham Bioechnologies). Cleaved Scs2p protein was loaded
nto a fast flow Hi-Trap Q (Pharmacia) column and eluted with a
inear gradient of sodium chloride from 100 mM to 200 mM. Scs2p
rotein-containing fractions were pooled before flash freezing 25
l aliquots in liquid nitrogen for storage at −80°C.
rotein Crystallization
elenomethionine-substituted VAP-A (1–125) was thawed, and
rystals were grown by vapor diffusion using sitting drops formed
y mixing a 1:1 volume ratio of 25 mg/ml VAP with an equilibration
uffer consisting of 30% polyethylene glycol monometheyl ether
molecular weight 2000), 200 mM NaCl, 25 mM Tris buffer (pH 7.5).
rystals formed over 1–3 weeks at 10°C in the space group P42212,
ith unit cell dimensions a = b = 45 Å, c = 112 Å, and contained
ne molecule per asymmetric unit with 45% solvent. For crystalli-
ation of the VAP-FFAT motif complex, a 2:1 molar ratio of peptide:-
AP-A (1–125) was mixed to produce a protein solution with 2.5
M peptide, 1.25 mM VAP, 6.8 mM DTT, 6.4 mM PIPES (pH 7.4).
small initial crystal grew in Hampton Research screen IndexHT
ondition H11, and subsequent crystals were grown by vapor diffu-
ion using macroseeded sitting drops formed by mixing a 1:1 vol-
me ratio of protein solution with an equilibration buffer consisting
f 27% polyethylene glycol monometheyl ether (molecular weight
000), 100 mM sodium thiocyanate, 100 mM Tris buffer (pH 7.4).
rystals formed in space group P1 (see below), with unit cell di-
ensions a = 50.1 Å, b = 50.0 Å, c = 90.3 Å, α = 90°, β = 90°, γ = 60°,
nd contained six molecules per asymmetric unit with 45% solvent.
rystallographic Data Collection
rystals were removed from sitting drops with a nylon loop and
ere transferred to a cryoprotectant solution composed of equili-
ration buffer supplemented with 15% ethylene glycol. Crystals
ere then flash frozen directly in a 100 K cryostream, and diffrac-
ion data were collected at beamline 8.2.1 of the Advanced Light
ource using an ADSC Quantum-210 CCD detector. For the VAP-A
1–125) MAD experiment, oscillation diffraction data were collected
o dmin = 1.7 Å resolution using inverse beam geometry in 15°
edges with all three wavelengths collected within each wedge
Table 1). For the VAP-FFAT complex, SAD oscillation diffraction data
VAP-FFAT Complex Structure
1043Figure 6. Overexpression of Full-Length VAP or an FFAT Binding Mutant Causes Altered ER Morphology
All scale bars represent 10 m.
(A) Full-length VAP-GFP (green) expressed in COS7 cells displays a pattern typical for ER proteins. The boxed area is shown in detail in the
right-hand panels (top panel, calreticulin; red, bottom panel; VAP-GFP, and calreticulin overlay).
(B) VAP-GFP does not overlay with microtubules. The boxed area is enlarged to show a detailed view of microtubules (red) and VAP-GFP
(right panel).
(C) VAP-GFP overexpression often results in areas of intense fluorescence that are continuous with normal-appearing ER (see inset).
(D) Intense fluorescent patches colocalize with calreticulin (red, right panel), indicating that they are likely composed of ER membrane.
(E) A very dense network of ER fills significant areas of the cytoplasm in many cells overexpressing VAP-GFP. The boxed area is shown in
detail in the right-hand panels (VAP-GFP, calreticulin, overlay).
(F) These areas of denser ER are more commonly seen in VAP K87D/M89D-GFP-expressing cells.
(G and H) Unlike wild-type VAP, VAP K87D/M89-GFP localizes in some cells to regularly spaced areas of intense fluorescence that are
continuous with normal-appearing ER and contain calnexin (red).
Structure
1044were collected at the selenium peak wavelength to dmin = 2.8 Å reso- p
wlution using inverse beam geometry in 5° wedges, and a native
diffraction data set to dmin = 1.9 Å resolution was also collected a
(Table 2). Diffraction data were processed with Mosflm/Scala
(CCP4, 1994). F
F
1Structure Determination and Refinement
(For VAP-A (1–125), the six expected selenium sites were found in
ianomalous difference Patterson maps calculated using the peak
iwavelength with an automated Patterson heavy atom search method
s(Grosse-Kunstleve and Brunger, 1999). MAD phasing and density
hmodification were carried out in CNS (Brunger et al., 1998) and
tresulted in a readily interpretable experimental electron density
bmap. A partial model was built automatically with wARP (Perrakis
get al., 1999), and the remainder of the model was built with the
tprogram O (Jones et al., 1991). Model refinement was monitored
susing the free R value (Brunger, 1992) computed from a randomly
vomitted 10% of the observed diffraction data. Refinement was car-
(ried out in CNS using alternating rounds of simulated annealing,
rtorsion angle molecular dynamics (Rice and Brunger, 1994), re-
cstrained B factor refinement (Hendrickson, 1985), and model re-
Gbuilding. The final model contains one N-terminal expression-con-
struct-derived residue, followed by residues 1–125 of VAP. The final
model has excellent stereochemistry (no residues in the disallowed
region of the Ramachandran plot), and R and Rfree values of 22.1% S
and 24.2%, respectively. S
The VAP-FFAT complex crystallized in space group P1. Although o
data could be processed in space group P3(2)21, a 1 Å translation M
along Z for molecules obeying the symmetry operators [x − y, −y, a
−z + 1/3], [−x, −x + y, −z − 1/3], or [y, x, −z] caused refinement to
converge poorly. Electron density for the bound FFAT peptide was A
clear, and refinement proceeded normally in space group P1. The
36 selenium sites from the 6 VAP molecules in the P1 cell were W
found by molecular replacement using the VAP-A (1–125) model in K
CNS. SAD phasing and density modification were carried out in s
CNS using a molecular envelope generated with the VAP-A D
(1–125) coordinates with MAMA (Kleywegt and Jones, 1999). Den- R
sity-modified SAD phases were of reasonable quality. After minor R
rebuilding of the VAP-A (1–125) model and addition of residues m
from the FFAT peptide, refinement was carried out in CNS with SAD l
experimental phases as outlined above. The bulk anisotropic B fac- a
tor was somewhat high, and addition of individual restrained B fac- t
tors showed no improvement over group-restrained B factor refine- U
ment. Translation, libration, and screw rotation (TLS) refinement S
(Winn et al., 2001) in REFMAC with six TLS groups, each consisting t
of a VAP-A (1–125) domain with bound peptide, improved both Rfree R
and R values by 3%–4%. Tight NCS restraints were used for all f
atoms throughout refinement. The final model contains ORP1 resi-
dues 473–481 and VAP residues 4–125, except for VAP residues 98
Rand 99, which had uninterpretable electron density. ORP1 residue
R472 was not observed, and side chain density was not observed
Afor ORP1 residues 473–475 (occupancies were set to zero for these
Presidues). The final model has no residues in the disallowed region
of the Ramachandran plot and R and Rfree values of 22% and 26%,




tNative gel electrophoresis was carried out using 8%–25% native
Phast (Pharmacia) gels with native buffer strips (0.88 M L-alanine, B
0.25 M Tris [pH 8.8], and 1 mM EDTA). Samples were mixed and c
incubated for at least 30 min in 50 mM HEPES (pH 7.5), 150 mM I
NaCl, 5 mM DTT before loading the gel. B
E
Yeast Growth Assay i
SCS2 was amplified from genomic DNA with upstream primer 5#-
B
GTCAGAGCACTGAACGAGG-3# and downstream primer 5#-CGC
v
CTACTACACTAGGGAAACC-3#. The PCR product contained the
BSCS2 cDNA sequence (CDS), plus 506 bp upstream and 287 bp
adownstream of the SCS2 gene. The PCR product was first inserted
into the pCR-Blunt II-TOPO vector (Invitrogen) and then subcloned B
Gas an EcoRI fragment into pRS313 (Sikorski and Hieter, 1989) and
sequenced. Yeast growth assays were performed by making a sus- Pension of w2 × 10−7 cells per ml, and a series of 10-fold dilutions
ere spotted onto SDC −inositol −histidine medium and incubated
t 37°C for 2 days.
luorescence Microscopy and Image Processing
or experiments in COS7 cells, full-length rat VAP-A (residues
–242) was subcloned as an XhoI-HindIII fragment in pEGFP-N1
Clontech) and confirmed by sequencing. COS7 cells were grown
n DMEM with 10% serum. Cells were transfected with Lipofectam-
ne 2000 (Invitrogen) and plated on collagen-coated glass cover-
lips. Cells were fixed 48 hr after transfection in 4% paraformalde-
yde or 0.3% glutaraldehyde for costaining of microtubules. For
ubulin staining, DM1α (Sigma) was used at 1/500. Polyclonal anti-
odies to calnexin and calrecticulin were diluted 1/1000 (Stress-
en). Cells were mounted in Vectashield mounting medium or Vec-
ashield with DAPI (Vector Laboratories, Burlingame, CA). Image z
tacks were collected in 0.20 m steps on an Olympus IX-70 in-
erted microscope with a 60X 1.4 N.A. oil-immersion objective
Olympus) and were captured by a cooled CCD camera (Photomet-
ics). Images were collected and processed with Delta Vision de-
onvolution software (Applied Precision, Seattle, WA) on a Silicon
raphics workstation (Silicon Graphics).
upplemental Data
upplemental Data including Figure S1, which contains alignments
f VAP and FFAT proteins, and Figure S2, which contains SEC-
ALLS analysis of VAP-FFAT complex solution behavior, are avail-
ble at http://www.structure.org/cgi/content/full/13/7/1035/DC1/.
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The VAP-A (1–125) and VAP-A (1–125) + FFAT complexes were de-
posited in the Protein Data Bank under codes 1Z9L and 1Z9O, re-
spectively.
